The correlation between allergic rhinitis and sleep disturbance

Timothy Craig, Jeffrey L. McCann, Faina Gurevich, Michael J. Davies

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Nasal congestion, a common symptom related to allergic rhinitis (AR), often is associated with poor sleep quality, leading to decreased learning ability, decreased productivity at work or school, and a reduced quality of life. The release of inflammatory mediators and activation of inflammatory cells results in nasal congestion, causing disrupted sleep and subsequent daytime somnolence. Therefore it is important to treat AR with medications that improve congestive symptoms without exacerbating sedation. Second-generation antihistamines and anticholinergic drugs are well tolerated but have little effect on congestion and therefore are limited in their ability to reduce AR-associated daytime somnolence. However, intranasal corticosteroids reduce congestion, improve sleep and sleep problems, and reduce daytime sleepiness, fatigue, and inflammation. Recently, montelukast, a leukotriene receptor antagonist, has joined the approved therapies for AR. Montelukast significantly improves both daytime and nighttime symptoms. AR treatment should endeavor to improve daytime and nighttime symptoms, sleep, and productivity, thereby improving quality of life.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
Volume114
Issue number5 SUPPL.
DOIs
StatePublished - Nov 1 2004

Fingerprint

montelukast
Sleep
Aptitude
Nose
Non-Sedating Histamine H1 Antagonists
Quality of Life
Efficiency
Leukotriene Antagonists
Cholinergic Antagonists
Fatigue
Adrenal Cortex Hormones
Allergic Rhinitis
Learning
Inflammation
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Craig, Timothy ; McCann, Jeffrey L. ; Gurevich, Faina ; Davies, Michael J. / The correlation between allergic rhinitis and sleep disturbance. In: Journal of Allergy and Clinical Immunology. 2004 ; Vol. 114, No. 5 SUPPL.
@article{8c281e21a1bb4e5fb79ebbb0d962a41b,
title = "The correlation between allergic rhinitis and sleep disturbance",
abstract = "Nasal congestion, a common symptom related to allergic rhinitis (AR), often is associated with poor sleep quality, leading to decreased learning ability, decreased productivity at work or school, and a reduced quality of life. The release of inflammatory mediators and activation of inflammatory cells results in nasal congestion, causing disrupted sleep and subsequent daytime somnolence. Therefore it is important to treat AR with medications that improve congestive symptoms without exacerbating sedation. Second-generation antihistamines and anticholinergic drugs are well tolerated but have little effect on congestion and therefore are limited in their ability to reduce AR-associated daytime somnolence. However, intranasal corticosteroids reduce congestion, improve sleep and sleep problems, and reduce daytime sleepiness, fatigue, and inflammation. Recently, montelukast, a leukotriene receptor antagonist, has joined the approved therapies for AR. Montelukast significantly improves both daytime and nighttime symptoms. AR treatment should endeavor to improve daytime and nighttime symptoms, sleep, and productivity, thereby improving quality of life.",
author = "Timothy Craig and McCann, {Jeffrey L.} and Faina Gurevich and Davies, {Michael J.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.jaci.2004.08.044",
language = "English (US)",
volume = "114",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5 SUPPL.",

}

The correlation between allergic rhinitis and sleep disturbance. / Craig, Timothy; McCann, Jeffrey L.; Gurevich, Faina; Davies, Michael J.

In: Journal of Allergy and Clinical Immunology, Vol. 114, No. 5 SUPPL., 01.11.2004.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The correlation between allergic rhinitis and sleep disturbance

AU - Craig, Timothy

AU - McCann, Jeffrey L.

AU - Gurevich, Faina

AU - Davies, Michael J.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Nasal congestion, a common symptom related to allergic rhinitis (AR), often is associated with poor sleep quality, leading to decreased learning ability, decreased productivity at work or school, and a reduced quality of life. The release of inflammatory mediators and activation of inflammatory cells results in nasal congestion, causing disrupted sleep and subsequent daytime somnolence. Therefore it is important to treat AR with medications that improve congestive symptoms without exacerbating sedation. Second-generation antihistamines and anticholinergic drugs are well tolerated but have little effect on congestion and therefore are limited in their ability to reduce AR-associated daytime somnolence. However, intranasal corticosteroids reduce congestion, improve sleep and sleep problems, and reduce daytime sleepiness, fatigue, and inflammation. Recently, montelukast, a leukotriene receptor antagonist, has joined the approved therapies for AR. Montelukast significantly improves both daytime and nighttime symptoms. AR treatment should endeavor to improve daytime and nighttime symptoms, sleep, and productivity, thereby improving quality of life.

AB - Nasal congestion, a common symptom related to allergic rhinitis (AR), often is associated with poor sleep quality, leading to decreased learning ability, decreased productivity at work or school, and a reduced quality of life. The release of inflammatory mediators and activation of inflammatory cells results in nasal congestion, causing disrupted sleep and subsequent daytime somnolence. Therefore it is important to treat AR with medications that improve congestive symptoms without exacerbating sedation. Second-generation antihistamines and anticholinergic drugs are well tolerated but have little effect on congestion and therefore are limited in their ability to reduce AR-associated daytime somnolence. However, intranasal corticosteroids reduce congestion, improve sleep and sleep problems, and reduce daytime sleepiness, fatigue, and inflammation. Recently, montelukast, a leukotriene receptor antagonist, has joined the approved therapies for AR. Montelukast significantly improves both daytime and nighttime symptoms. AR treatment should endeavor to improve daytime and nighttime symptoms, sleep, and productivity, thereby improving quality of life.

UR - http://www.scopus.com/inward/record.url?scp=7444248464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444248464&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2004.08.044

DO - 10.1016/j.jaci.2004.08.044

M3 - Article

C2 - 15536445

AN - SCOPUS:7444248464

VL - 114

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5 SUPPL.

ER -